Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | FLT1 | P17948 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | FLT4 | P35916 | 2/20 | 0.48 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 9/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | KIF5B | P33176 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31472862 | 1.00 | KDR (0.48) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL28797709 | 0.89 | KDR (0.45) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL29924080 | 0.86 | EGFR (0.50) | KDRFLT1EPHB2EGFRABCG2 | |
| SCHEMBL29718969 | 0.86 | EGFR (0.50) | EGFRABCG2 | |
| SCHEMBL29924017 | 0.86 | EGFR (0.50) | EGFRABCG2 | |
| SCHEMBL22983661 | 0.86 | EGFR (0.50) | KDRFLT1EPHB2EGFRABCG2 | |
| SCHEMBL29719083 | 0.86 | EGFR (0.50) | KDRFLT1EPHB2EGFRABCG2 | |
| SCHEMBL22983644 | 0.86 | EGFR (0.50) | EGFRABCG2 | |
| SCHEMBL22983424 | 0.82 | KDR (0.50) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL31472883 | 0.82 | KDR (0.50) | KDRFLT1FGFR1FLT4EPHB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220298120-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114787150-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4013749-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | Black Diamond Therapeutics, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021030711-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | KDR 917/4885FLT1 1932/4885FGFR1 242/4885 |
| US-20220298120-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | GLS, GLS2, MCL1 | KDR 917/4885FLT1 1932/4885FGFR1 242/4885 |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | KDR 1101/4885FLT1 1508/4885FGFR1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.